FDA/CMS Parallel Review: Firms Lack Incentive To Participate, Lawyers Say

As drug industry advisors scrutinize FDA’s and CMS’ recent proposal to institute voluntary parallel reviews of new medical products, some are seeing little reason for manufacturers to subject their products to parallel review.